7 min read
ASCO 2026: Next-Generation Immunotherapies
A look at where personalized mRNA cancer vaccines, in vivo CAR-T and TIL therapies stand after this year’s meeting
...
🔬 Connecting with the Global Biopharma Community
Veristat is pleased to attend BIO-Europe Spring, where biotech innovators, investors, and development leaders come together to form the partnerships that move new therapies forward. As sponsors advance programs through early and mid-stage development, success increasingly depends on disciplined planning, high-quality evidence, and regulatory clarity.
Our team looks forward to meeting with biotech leaders to discuss how Veristat helps sponsors move complex therapies forward while making every dollar of development capital count.
👥 Meet the Veristat Team at BIO-Europe Spring
Connect with our experts to explore how Veristat’s scientific leadership and focused capabilities can help advance your clinical and regulatory milestones.
-
Balma Gill, Business Development Director
📅 Schedule a meeting in advance
By completing the form on this page. We welcome the opportunity to discuss your upcoming programs and how Veristat can be a strategic partner in your success.
💡 Our Expertise
Veristat’s work centers on the capabilities sponsors need most as programs move from early clinical development toward regulatory submission:
-
Phase I–II Clinical Development
-
Biostatistics and Data-Driven Evidence
-
Regulatory Strategy and Medical Writing
Together, these capabilities help sponsors move confidently from study design to regulatory submission while preserving valuable development capital and accelerating progress toward patients.
Schedule A Meeting
Meet with us at BIO-Europe Spring in Lisbon, Portugal
4 min read
ASCO 2026: RAS Is No Longer Undruggable
Jun 15, 2026 Veristat News
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...